BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Alzheimer's disease clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for Alzheimer disease: 215 (144 sponsors; 48 newly posted in the last 180 days, 8 stopped in the last 180 days; 27 new-entrant sponsors). Momentum score 21.2, rank 25 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 2, Phase 1 42, Phase 2 55, Phase 3 53, Phase 4 7, N/A 56.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Eli Lilly and Company LLY20P4 1, P3 8, NA 4, P1 6, P2 150
Bristol-Myers Squibb BMY8P3 6, P1 1, P2 111
Hoffmann-La Roche8P3 4, P2 3, P1 122
Karuna Therapeutics, Inc., a Bristol Myers Squibb company4P3 402
Eisai Inc.7P3 2, P2 1, NA 3, P1 142
Eidos Therapeutics, a BridgeBio company3P4 1, P3 210
ACADIA Pharmaceuticals Inc. ACAD2P3 200
Annovis Bio Inc. ANVS2P3 210
JYAMS PET Research & Development Limited2P3 212
AB Science1P3 100
Actinogen Medical1P3 100
AriBio Co., Ltd.1P3 100
Benuvia Therapeutics Inc.1P3 100
Bigespas LTD1P3 101
Cerecin1P3 100
CereMark Pharma, LLC1P3 100
Danyang Huichuang Medical Equipment Co., Ltd.1P3 100
Exciva GmbH1P3 100
HTA Co., Ltd. new entrant1P3 110
Incyte Corporation INCY1P3 100
Lantheus Biosciences Ltd. LNTH1P3 100
Moleac Pte Ltd.1P3 100
Samsung Pharmaceutical Co., Ltd.1P3 100
ScandiBio Therapeutics AB1P3 100
Sichuan Jishengtang Pharmaceutical Co., Ltd.1P3 100

New-entrant sponsors: HTA Co., Ltd..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-19 est.P2Hoffmann-La RocheNCT06402838 A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)Alzheimer's Diseaseactive not recruiting256
2026-11-24 est.P3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT06585787 A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Alzheimer Diseaserecruiting406
2026-12 est.P3Suven Life Sciences LimitedNCT05397639 Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's TypeAgitation; Alzheimer's Type Dementiaactive not recruiting375
2026-12-01 est.P3JYAMS PET Research & Development LimitedNCT07422857 Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive FunctionSubjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementiarecruiting316
2026-12-03 est.P2Eisai Inc.NCT06602258 A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseaseAlzheimer's Diseaseactive not recruiting105
2026-12-09 est.P3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT06126224 A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Psychosis Associated With Alzheimer's Diseaserecruiting500
2026-12-17 est.P2Bristol-Myers Squibb BMYNCT06268886 Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's DiseaseAlzheimer Disease, Early Onsetactive not recruiting310
2026-12-22 est.P2Janssen Pharmaceutica N.V., BelgiumNCT06544616 A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseAlzheimer Diseaseactive not recruiting55
2026-12-31 est.P3Eisai Inc.NCT03887455 A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseEarly Alzheimer's Diseaseactive not recruiting1906
2026-12-31 est.P2ExcelsiorNCT05413655 A Study of Oral EX039 in Subjects with Mild Alzheimer's DiseaseAlzheimer Diseaserecruiting120
2026-12-31 est.P2Ono Pharmaceutical Co., Ltd.NCT06803823 A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease DementiaAgitation Associated With Alzheimer's Disease Dementiarecruiting90

FDA decision events (last 12 months and upcoming)

DateEventStatusCompanyDrugSource
2027-05-01PDUFA date (company-disclosed)pendingAxsome Therapeutics, Inc. AXSMPDUFA May 1, 2027 - Axsome Therapeutics, Inc.

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2IGC Pharma, LLC IGCNCT05543681 Clinical Trial on Agitation in Alzheimer's DementiaAlzheimer Disease; Agitation,Psychomotor; Care Giving Burden; NPS; Aggressionactive not recruiting164
2026-10-29P2Acumen Pharmaceuticals ABOSNCT06335173 A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)Alzheimer Diseaseactive not recruiting542
2026-10-13P1/P2Voyager Therapeutics VYGRNCT06874621 VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's DiseaseAlzheimer's Disease (AD)active not recruiting52
2026-10-05 est.P3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT05511363 A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)Psychosis Associated With Alzheimer's Diseaserecruiting410
2026-09-22P2/P3Actinogen MedicalNCT06125951 Effect of 10 mg Xanamem on Dementia Due to Alzheimer's DiseaseDementia Moderate; Dementia, Mild; Alzheimer Diseaseactive not recruiting247
2026-09 est.P3ScandiBio Therapeutics ABNCT07062198 Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's DiseaseAlzheimer Diseaserecruiting845
2026-08-31 est.P3Sichuan Jishengtang Pharmaceutical Co., Ltd.NCT06534723 Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)Alzheimer's Dementiarecruiting570
2026-07-31P2Ono Pharmaceutical Co., Ltd.NCT06881836 A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's DiseaseAlzheimer Diseasecompleted260
2026-07-30 est.P1/P2NSC-TherapeuticsNCT06995573 A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's DiseaseAlzheimer Diseaserecruiting90
2026-06-29P3AriBio Co., Ltd.NCT05531526 Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (PolariAlzheimer Diseaseactive not recruiting1535
2026-06-05P2Merck Sharp & Dohme LLC MRKNCT06721156 A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)Alzheimer Disease; Dementiaterminated369

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "Alzheimer disease"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.